Alector, Inc. (ALEC)
$
1.33
-0.09 (-6.77%)
Key metrics
Financial statements
Free cash flow per share
-2.3148
Market cap
125 Million
Price to sales ratio
1.4149
Debt to equity
0.4339
Current ratio
3.3401
Income quality
1.8579
Average inventory
0
ROE
-1.0058
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s EBITDA is -$136,156,000.00 a key indicator of its operational profitability. Alongside this, Alector reported depreciation and amortization expenses of $8,841,000.00 reflecting the wear and tear of its assets. Its gross profit ratio stands at 0.91 illustrating the efficiency of the company’s production and sales operations. Furthermore, the diluted EPS is -$1.23 accounting for potential share dilution. The company's stock is identified with the symbol 'ALEC' in the market, making it accessible for investors interested in its innovative offerings. Alector’s product pipeline includes AL001, a humanized recombinant monoclonal antibody, currently in Phase III clinical trials for treating frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. Additionally, AL101 is undergoing Phase I clinical trials for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company also has AL002, a product candidate in Phase II trials for Alzheimer's disease, and AL003, which is in Phase I trials. Moreover, AL044, aimed at MS4A4A, a risk gene for Alzheimer's, is in the development stage. Alector maintains a collaboration agreement with Adimab, LLC for antibody research and development, as well as a strategic collaboration with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies like AL001 and AL101. The stock is affordable at $1.42 making it suitable for budget-conscious investors. It also boasts a high average trading volume of 918,869.00 indicating strong liquidity. With a market capitalization of $132,990,158.00 Alector is classified as a small-cap player in the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Alector, Inc. (ALEC) a good investment?
Investing in Alector, Inc. (ALEC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Alector, Inc. (ALEC)'s stock forecast?
Analysts predict Alector, Inc. stock to fluctuate between $0.87 (low) and $6.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alector, Inc.'s market capitalization?
As of 2025-05-30, Alector, Inc.'s market cap is $132,990,158, based on 99,992,600 outstanding shares.
How does Alector, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alector, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alector, Inc. (ALEC) stock?
To buy Alector, Inc. (ALEC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALEC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alector, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Alector, Inc. perform in the last earnings report?
Revenue: $100,558,000 | EPS: -$1.23 | Growth: -21.15%.
Where can I find Alector, Inc.'s investor relations reports?
Visit https://www.alector.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alector, Inc.?
You can explore historical data from here
What is the all-time high and low for Alector, Inc. stock?
All-time high: $43.32 (2021-07-02) | All-time low: $0.87 (2025-04-09).
What are the key trends affecting Alector, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
23 days ago
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates.
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m.
globenewswire.com
a month ago
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD).
globenewswire.com
2 months ago
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
seekingalpha.com
3 months ago
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
zacks.com
3 months ago
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
globenewswire.com
3 months ago
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m.
globenewswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
globenewswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.
globenewswire.com
5 months ago
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration
See all news
